Effects of contraceptive use on bone biochemical markers in young women

Journal of Clinical Endocrinology and Metabolism

Volumn 86, Issue 1, 2001, Pages 179-185

  Ott, Susan M ^a   Scholes, Delia ^a   Lacroix, Andrea Z ^a   Ichikawa, Laura E ^b   Yoshida, Cathleen K ^b   Barlow, William E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b CENTER FOR HEALTH STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATININE; ESTROGEN; GESTAGEN; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; OSTEOCALCIN; PARATHYROID HORMONE;

ADULT; ARTICLE; BONE DENSITY; CONTRACEPTION; DENSITOMETRY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HORMONAL CONTRACEPTION; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PREMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR;

ADULT; BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE RESORPTION; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL; DELAYED-ACTION PREPARATIONS; ESTROGENS; FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; OSTEOCALCIN; OSTEOGENESIS; PREMENOPAUSE; PROGESTINS;

EID: 0035142204     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.86.1.179     Document Type: Article

References (49)

1. Bone mineral density in women using depot medroxyprogesterone acetate for contraception
2. Long-term depot-medroxyprogesterone acetate and bone mineral density
3. Forearm bone density in users of Depo-Provera as a contraceptive method
4. Bone density among long-term users of medroxyprogesterone acetate as a contraceptive
5. Bone density in long term users of depot medroxyprogesterone acetate
6. Spinal bone density in women using depot medroxyprogesterone contraception
7. Bone gain in young adult women
8. Bone mineral density in postmenopausal women as determined by prior oral contraceptive use
9. Oral contraceptive use may protect against low bone mass
10. Oral contraceptive use and risk of hip fracture: A case-control study
11. Bone mass and long-term monophasic oral contraceptive treatment in young women
12. Biochemical aspects of hormonal contraception: Effects on bone metabolism
13. Determinants of premenopausal bone mineral density: The interplay of genetic and lifestyle factors
14. Decreased bone turnover in oral contraceptive users
15. Bone density in premenopausal women: Effects of age, dietary intake, physical activity, smoking, and birth-control pills
16. Bone density in a population of long term oral contraceptive pill users does not differ from that in menstruating women
17. Lack of relationship between hip and spine bone mineral density and oral contraceptive use
18. Bone mineral density and history of oral contraceptive use
19. Oral contraceptive pill use and fractures in women: A prospective study
20. Osteocalcin and bone morphometric parameters in adults without bone disease
21. Quantification of biochemical markers of bone turnover by kinetic measures of bone formation and resorption in young healthy females
22. Design of the Fracture Intervention Trial
23. Bone protein and peptide assays in the diagnosis and management of skeletal disease
24. The new, practical intraoperative parathyroid hormone assay
25. A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urine
26. Circadian variation in urinary excretion o bone collagen cross-links
27. Food frequency questionnaires for diet intervention research
28. Peak bone mass in young women
29. Premenopausal bone loss in the lumbar spine and neck of femur: A study of 225 Caucasian women
30. Bone resorption rates in children monitored by the urinary assay of collagen type I cross-linked peptides
31. Serum bone Gla-protein as a marker of bone growth in children and adolescents: Correlation with age, height, serum insulin-like growth factor I, and serum testosterone
32. Changes in bone resorption during the menstrual cycle
33. Androgens and osteocalcin during the menstrual cycle
34. Urinary biochemical markers for bone resorption during the menstrual cycle
35. Differential effects on bone density of progestogen-only methods for contraception in premenopausal women
36. Amenorrheic bone loss
37. The effects of continuous progestogen treatment on cortcal bone remodeling activity in beagles
38. Bone density effects of continuous estrone sulfate and varying doses of medroxyprogesterone acetate
39. A double-blind randomised controlled trial of the effects of medroxyprogesterone acetate on bone density of women taking oestrogen replacement therapy
40. Effects of hormone therapy on bone mineral density: Results from the postmenopausal estrogen/progestin interventions (PEPI) trial
41. Medroxyprogesterone acetate with zoladex for long-term treatment of fibroids: Effects on bone density and patient acceptability
42. Premenopausal ovariectomy-related bone loss: A randomized, double- blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate
43. Bone mineral changes in young women with hypothalamic amenorrhea treated with oral contraceptives, medroxyprogesterone, or placebo over 12 months
44. Cyclic medroxyprogesterone treatment increases bone density: A controlled trial in active women with menstrual cycle disturbances
45. Biochemical markers of bone turnover in lactating and nonlactating postpartum women
46. Recovery of bone density in women who stop using medroxyprogesterone acetate
47. Assessment of age and risk factors on bone density and bone turnover in healthy premenopausal women
48. Oral contraceptive treatment inhibits the normal acquisition of bone mineral in skeletally immature young adult female monkeys
49. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis